KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Operating Income (2016 - 2025)

Historic Operating Income for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $8.9 billion.

  • Eli Lilly's Operating Income rose 6680.34% to $8.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $29.2 billion, marking a year-over-year increase of 8055.57%. This contributed to the annual value of $29.2 billion for FY2025, which is 8055.5% up from last year.
  • Eli Lilly's Operating Income amounted to $8.9 billion in Q4 2025, which was up 6680.34% from $8.0 billion recorded in Q3 2025.
  • Eli Lilly's 5-year Operating Income high stood at $8.9 billion for Q4 2025, and its period low was $1.4 billion during Q2 2021.
  • For the 5-year period, Eli Lilly's Operating Income averaged around $3.6 billion, with its median value being $2.6 billion (2022).
  • As far as peak fluctuations go, Eli Lilly's Operating Income crashed by 3777.97% in 2023, and later soared by 10106.13% in 2025.
  • Eli Lilly's Operating Income (Quarter) stood at $2.4 billion in 2021, then fell by 11.82% to $2.1 billion in 2022, then skyrocketed by 44.94% to $3.0 billion in 2023, then surged by 77.35% to $5.3 billion in 2024, then skyrocketed by 66.8% to $8.9 billion in 2025.
  • Its last three reported values are $8.9 billion in Q4 2025, $8.0 billion for Q3 2025, and $7.0 billion during Q2 2025.